PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast

Go online to PeerView.com/MXF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this infographic-based activity, an expert in sleep medicine discusses the signs and symptoms of narcolepsy and shares evidence-based approaches to individualizing care. Upon completion of this accredited CE activity, participants should be better able to: Apply criteria for the diagnosis of narcolepsy with or without cataplexy, Evaluate evidence regarding the role of oxybate formulations in the treatment of adults and children who have narcolepsy with or without cataplexy, including mechanistic effects on the underlying pathophysiology, Incorporate oxybate formulations as part of individualized regimens for treating narcolepsy, with or without cataplexy, considering comorbid conditions, disease burden, patient preferences, and quality of life.

Go online to PeerView.com/XTM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in interstitial lung diseases discuss the signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD; how to interpret radiographic patterns on HRCT to facilitate an accurate diagnosis; and the importance of the multidisciplinary team. Upon completion of this activity, participants should be better able to: Describe signs and symptoms of ILDs, including IPF, SSc-ILD, and CF-ILD, that would warrant further evaluation, Interpret radiographic patterns on HRCT to facilitate the differential diagnosis of ILDs, including IPF, SSc-ILD, and CF-ILD, Discuss the use of HRCT to monitor disease progression in patients with ILD, Employ collaborative approaches as part of a multidisciplinary team to diagnose ILDs, including IPF, SSc-ILD, and CF-ILD.

Go online to PeerView.com/EME860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts discuss recent updates to recommendations in the diagnosis, surveillance, and management of tuberous sclerosis complex. Upon completion of this activity, participants should be better able to: Utilize clinical and genetic diagnostic criteria to identify patients with tuberous sclerosis complex (TSC) early in the disease course, Employ updated consensus recommendations for the surveillance of patients with TSC throughout the course of their disease, Apply updated consensus recommendations for the management of patients with specific disease manifestations associated with TSC.

Go online to PeerView.com/DXP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in pediatric rheumatology discusses contemporary approaches to improve the care of patients with polyarticular juvenile idiopathic arthritis. Upon completion of this activity, participants should be better able to: Identify the clinical manifestations of polyarticular juvenile idiopathic arthritis (pJIA), Employ appropriate inclusion and exclusion criteria to facilitate an early and accurate diagnosis of pJIA, Recognize the mechanism of action, efficacy, and safety of current treatment approaches to pJIA, Select appropriate treatment for individual patients with pJIA in accordance with current evidence and expert recommendations, considering disease activity and severity as well as patient/caregiver needs and preferences.

Go online to PeerView.com/VWY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in emergency medicine discusses the diagnosis and management of patients with migraine in the emergency department setting. Upon completion of this accredited CE activity, participants should be better able to: Identify best practices and current recommendations for diagnosing patients with migraine, including risk-stratification strategies for performing a differential diagnosis in the emergency department (ED); Apply evidence-based criteria and screening tools to accurately diagnose patients presenting to the ED with migraine; Summarize data on the efficacy, safety, and tolerability of agents currently available for the acute treatment and prevention of migraine; Employ strategies to help coordinate outpatient care and integrate current therapies into personalized management plans for acute treatment and prevention of migraine.

Go online to PeerView.com/QQN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses the current clinical data and practical application of disease-modifying therapies in the management of patients with spinal muscular atrophy. Upon completion of this activity, participants should be better able to: Identify spinal muscular atrophy (SMA) through newborn screening and/or recognition of symptoms and signs, Apply current evidence on the efficacy, safety, and tolerability of approved disease-modifying therapies in the treatment of SMA, Counsel caregivers and/or patients regarding the need for monitoring and supportive care to optimize treatment outcomes in SMA.

Go online to PeerView.com/HKY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a leading expert in the management of acute hepatic porphyria (AHP) discusses recent evidence and recommendations for treating AHP and highlights the rationale and role of a new siRNA-based therapeutic option. Upon completion of this activity, participants should be better able to: Recognize AHP and associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Describe evidence-based interventions for AHP, including the rationale and trial data for recently approved siRNA therapy, Apply evidence-based diagnostic and treatment approaches to minimize disease impact and burden for individuals with AHP.

Go online to PeerView.com/WUH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses contemporary approaches to improve the care of patients with moderate to severe alopecia areata. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe alopecia areata, Discuss the rationale for JAK inhibition as a treatment approach to alopecia areata, Compare and contrast novel JAK inhibitors for the treatment of moderate to severe alopecia areata in the context of selectivity, efficacy, and safety, Treat moderate to severe alopecia areata in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from novel nonbiologic oral therapeutic options.

Go online to PeerView.com/ECW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses the role of IL-17 inhibitors in the treatment of psoriasis. Upon completion of this activity, participants should be better able to: Discuss the impact of psoriasis on patient quality of life, Outline the role of IL-17 in the pathophysiology of psoriasis, Assess data regarding the efficacy and safety of IL-17 inhibitors for the treatment of moderate to severe psoriasis, Incorporate agents targeting IL-17 into appropriate and effective treatment plans for individual patients with moderate to severe psoriasis.

Go online to PeerView.com/UNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a nephrology expert discusses the latest evidence for hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitors for the treatment of anemia associated with chronic kidney disease (CKD). Upon completion of this activity, participants will be able to: Describe the epidemiology, pathology, and burden of anemia associated with CKD, Discuss key limitations associated with the current model of treatment for anemia associated with CKD, including in patients with NDD-CKD and DD-CKD, Explain the rationale for and potential implications of targeting HIF stabilization with HIF-PH inhibitors as a treatment strategy for anemia in CKD.